{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:26:29Z","timestamp":1785115589321,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Lymphoplasma exchange (LPE), a technique combining plasma exchange with leukapheresis, is emerging as promising treatment for autoimmune diseases. Data on the efficacy and safety of LPE in myasthenia gravis (MG) therapy are scarce. In this study, we aimed to comprehensively review the clinical efficacy, safety, and immunological characteristics of LPE therapy in MG patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design and Methods<\/jats:title><jats:p>A Chinese cohort of 276 generalized MG patients in state of exacerbation, including impeding crisis, myasthenia crisis, and preparation for thoracic exsection between January 2014 and December 2020, were evaluated in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 276 patients with a median age of 45.5 \u00b1 16.7 years underwent a total of 635 LPE sessions. Clinical scales of Quantitative Myasthenia Gravis (QMG) scores, Myasthenia Gravis Specific Manual Muscle Testing (MMT) scores, activities of daily living (ADL) scores, and quality of life (QOL) scores were improved during 4 weeks\u2019 follow-up. Adverse effects occurred in 20 out of 276 patients, with 14 patients having one adverse event each. Independent predictive factors for good response to LPE therapy were symptom onset before LPE therapy \u22643 days and age on LPE therapy &amp;lt;50 years of age. LPE decreased the serum levels of antibodies, immunoglobulins, and complements 4 weeks after the first replacement, with decreased levels of interleukin (IL)-17A and interferon (IFN)-\u03b3 and increased level of IL-10.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LPE is an effective treatment for MG patients in state of exacerbation and preparation for thymectomy. Early use of LPE on early-onset MG may have good therapeutic effects. The potential mechanism for LPE is the polarization of cytokines from IL-17A, IFN-\u03b3, into IL-10.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.757841","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T05:10:11Z","timestamp":1649913011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center"],"prefix":"10.3389","volume":"13","author":[{"given":"Song","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092683","article-title":"Apheresis in Autoimmune Encephalitis and Autoimmune Dementia","volume":"9","author":"R\u00f6ssling","year":"2020","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2019-002336","article-title":"Plasma Exchange in Neurological Disease","volume":"20","author":"Osman","year":"2020","journal-title":"Pract Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00324","article-title":"Application of Plasma Exchange in Steroid-Responsive Encephalopathy","volume":"10","author":"Jiang","year":"2019","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2006.07.004","article-title":"CD4+ T and B Cells Cooperate in the Immunoregulation of Experimental Autoimmune Myasthenia Gravis","volume":"179","author":"Milani","year":"2006","journal-title":"J Neuroimmunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12974-017-0892-8","article-title":"Regulatory T Cells in Multiple Sclerosis and Myasthenia Gravis","volume":"14","author":"Danikowski","year":"2017","journal-title":"J Neuroinflammation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T Helper Type 1, 2 and 17 Cells and Regulatory T Cells During the Development of Experimental Autoimmu- Ne Myasthenia Gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002796","article-title":"Treating Myasthenia on Consensus Guide: Helpful and Challenging But Still Unfinished Business","volume":"87","author":"Marinos","year":"2016","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical Implication of Peripheral CD4+CD25+ Regulatory T Cells and Th17 Cells in Myasthenia Gravis Patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J Neuroimmunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920010105","article-title":"Use of Lymphoplasmapheresis or Plasmapheresis in the Management of Acute Renal Allograft Rejection","volume":"1","author":"Kleinman","year":"1982","journal-title":"J Clin Apher"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0000000000000238","article-title":"Quality of Life of Myasthenia Gravis Patients in Regard to Epidemiological and Clinical Characteristics of the Disease","volume":"24","author":"Stojanov","year":"2019","journal-title":"Neurologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.14715\/cmb\/2017.63.10.17","article-title":"Clinical Efficacy and Mechanism of Lymphoplasma Exchange in the Treatment of Guillain-Barre Syndrome","volume":"63","author":"Luo","year":"2017","journal-title":"Cell Mol Biol(Noisy-le-grand)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e14092","DOI":"10.1111\/dth.14092","article-title":"Successful Use of Lymphoplasma Exchange in a Patient With Acute Generalized Pustular Psoriasis of Von Zumbusch","volume":"33","author":"Zhang","year":"2020","journal-title":"Dermatol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163988.28892.79","article-title":"Quantitative Myasthenia Gravis Score: Assessment of Responsiveness and Longitudinal Validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15598","article-title":"Striking Case of Febrile Ulceronecrotic Mucha-Habermann Disease Responding to Lymphoplasmapheresis and Methotrexate","volume":"47","author":"Wang","year":"2020","journal-title":"J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/mus.26719","article-title":"Severity and Depression can Impact Quality of Life in Patients With Myasthenia Gravis","volume":"61","author":"Alanazy","year":"2020","journal-title":"Muscle Nerve"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21529","article-title":"Plasma Exchange in the Intensive Care Unit: Technical Aspects and Complications","volume":"32","author":"Lemaire","year":"2017","journal-title":"J Clin Apher"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2011.7.4.173","article-title":"Treatment of Myasthenia Gravis Based on its Immunopathogenesis","volume":"7","author":"Kim","year":"2011","journal-title":"J Clin Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21755","article-title":"Therapeutic Plasma Exchange may Adjust IL-6 and TGF-\u03b2 Signals in Relapsed MS Patients Peripheral Blood","volume":"35","author":"Jamshidian","year":"2020","journal-title":"J Clin Apher"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late-Onset Myasthenia Gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1594.2012.01531.x","article-title":"A Decrease in the Percentage of CD3+ Cells is Correlated With Clinical Improvement During Plasmapheresis in Patients With Myasthenia Gravis","volume":"37","author":"Chien","year":"2013","journal-title":"Artif Organs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of Therapeutic Plasma Exchange on Immunoglobulins in Myasthenia Gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2009.09.022","article-title":"T-Bet Deficiency Decreases Susceptibility to Experimental Myasthenia Gravis","volume":"220","author":"Liu","year":"2009","journal-title":"Exp Neurol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2005.10.001","article-title":"Altered Expression of Th1-Type Chemokine Receptor CXCR3 on CD4+ T Cells in Myasthenia Gravis Patients","volume":"172","author":"Suzuki","year":"2006","journal-title":"J Neuroimmunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00011-009-0087-6","article-title":"Suppression of Ongoing Experimental Autoimmune Myasthenia Gravis by Transfer of RelB-Silenced Bone Marrow Dentritic Cells is Associated With a Change From a T Helper Th17\/Th1 to a Th2 and FoxP3+ Regulatory T-Cell Profile","volume":"59","author":"Yang","year":"2010","journal-title":"Inflammation Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12865-017-0210-3","article-title":"The Cytokine Polymorphisms Affecting Th1\/Th2 Increase the Susceptibility to, and Severity of, Chronic ITP","volume":"18","author":"Takahashi","year":"2017","journal-title":"BMC Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000486037","article-title":"Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction After Thymectomy May Be Related to Disease Progression in Myasthenia Gravis","volume":"24","author":"Hosseini","year":"2017","journal-title":"Neuroimmunomodulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/imm.12322","article-title":"Neutralization of Interleukin-9 Ameliorates Symptoms of Experimental Autoimmune Myasthenia Gravis in Rats by Decreasing Effector T Cells and Altering Humoral Responses","volume":"143","author":"Yao","year":"2014","journal-title":"Immunology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2013.11.046","article-title":"Double Filtration Plasmapheresis Benefits Myasthenia Gravis Patients Through an Immunomodulatory Action","volume":"21","author":"Zhang","year":"2014","journal-title":"J Clin Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000596","article-title":"Myasthenia Gravis: From Autoantibodies to Therapy","volume":"31","author":"Mantegazza","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20342","article-title":"Effect of Plasma Exchange on Cytokines Measured by Multianalyte Bead Array in Thrombotic Thrombocytopenic Purpura","volume":"79","author":"Shariatmadar","year":"2005","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02729.x","article-title":"Changes in Serum Cytokine Levels During Plasmapheresis in Patients With Myasthenia Gravis","volume":"16","author":"Yeh","year":"2009","journal-title":"Eur J Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04547.x","article-title":"Can Plasma Exchange Therapy Induce Regulatory T Lymphocytes in Multiple Sclerosis Patients","volume":"168","author":"Jamshidian","year":"2012","journal-title":"Clin Exp Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21694","article-title":"Excellent Response to Therapeutic Plasma Exchange in Myasthenia Gravis Patients Irrespective of Antibody Status","volume":"34","author":"Usmani","year":"2019","journal-title":"J Clin Apher"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00725-4","article-title":"Efficacy of TherapeuticPlasma Exchange in Patients with Severe Refractory Anti-NMDA Receptor Encephalitis","volume":"16","author":"Zhang","year":"2019","journal-title":"Neurotherapeutics"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.03.009","article-title":"TGF-\u03b2 in Th17 Cell Development: The truth Is Out There","volume":"34","author":"Hatton","year":"2011","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.13925","article-title":"Therapeutic Plasma Exchange in Paediatric Neurology: A Critical Review and Proposed Treatment Algorithm","volume":"60","author":"Eyre","year":"2018","journal-title":"Evol Med Child Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.757841\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T05:10:25Z","timestamp":1649913025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.757841\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2022.757841"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.757841","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"article-number":"757841"}}